The Artificial Intellingence & Cancers Association offers two differentiating opportunities to project leaders.

Conducting a project with the AI & cancers Association means :

• Exposing yourself to an exceptional audience. The Association’s Board of Directors is made of the world’s leading industry companies in oncology, government agencies such as the French National Cancer Institute and the Health Data Hub, and professional associations dedicated to research and innovation in health : France Biotech and the Health Industry Alliance for Research and Innovation. This federated audience has the unprecedented capacity to deploy innovations for patients, to take its messages to the highest level and its innovations to the international level.

• Taking part in a close dialogue with the French National Authority for Health (HAS). As part of the Health Innovation 2030 Plan announced by the French President on 29 June 2021, and following the agreement of the Presidency of the National Authority for Health on 21 February 2022, the Association is building a long term dialogue with the latter on the issues raised by its projects. This measure is developed within the framework of the action 3.F of the Health Innovation 2030 Plan, entitled : “working towards the integration of trials based on innovative, real-life, adaptive, in silico methodologies”.